BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26918562)

  • 21. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
    Arias de la Vega F; Contreras J; de Las Heras M; de la Torre A; Arrazubi V; Herruzo I; Prieto I; García-Saenz JA; Romero J; Calvo FA;
    Ann Oncol; 2012 Apr; 23(4):1005-9. PubMed ID: 21778302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
    Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
    Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response.
    Eswaran P; Azmi KS
    J Cancer Res Ther; 2013; 9(3):392-6. PubMed ID: 24125972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M
    Clin Oncol (R Coll Radiol); 2005 May; 17(3):148-52. PubMed ID: 15900997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
    Noronha V; Goswami C; Patil S; Joshi A; Patil VM; Murthy V; Arya S; Juvekar S; Goud S; Prabhash K
    J Laryngol Otol; 2016 Sep; 130(9):833-42. PubMed ID: 27456399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
    Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
    Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
    Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
    Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
    Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer.
    Chitapanarux I; Lorvidhaya V; Tharavichitkul E; Mayurasakorn S; Sittitrai P; Pattarasakulchai T; Tananuwat R; Srivanitchapoom C
    Auris Nasus Larynx; 2011 Feb; 38(1):108-13. PubMed ID: 20591592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
    Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers.
    Baykara M; Buyukberber S; Ozturk B; Coskun U; Kaplan MA; Unsal DK; Dane F; Demirci U; Bora H; Benekli M;
    Tumori; 2013; 99(4):469-73. PubMed ID: 24326834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
    Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG
    Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
    Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
    Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.